NASDAQ: VORVor Biopharma Inc Stock
$13.16-1.16 (-8.1%)
Updated Jun 5, 2026
VOR Price
$13.16
Fair Value Price
$39.86
Market Cap
$713.09M
52 Week Low
$3.62
52 Week High
$65.80
P/E
-0.19x
P/B
-4.74x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$883.08M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-4.37
Operating Cash Flow
-$150M
Beta
1.23
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
VOR Overview
Vor Biopharma Incorporated develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients.VOR33 is in phase 1/2 trials to treat acute myeloid leukemia and other blood cancers. Vor Biopharma was incorporated in 2015 and is headquartered in Cambridge, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VOR's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
VOR
Ranked#314 of 464
Ranked#314 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $238.57 | A | |
| $6.18 | A | |
| $270.10 | A |
Be the first to know about important VOR news, forecast changes, insider trades & much more!
VOR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VOR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VOR ($13.16) is undervalued by 66.98% relative to our estimate of its Fair Value price of $39.86 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
VOR ($13.16) is significantly undervalued by 66.98% relative to our estimate of its Fair Value price of $39.86 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
VOR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VOR due diligence checks available for Premium users.
Valuation
VOR fair value
Fair Value of VOR stock based on Discounted Cash Flow (DCF)
Price
$13.16
Fair Value
$39.86
Undervalued by
66.98%
VOR ($13.16) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VOR ($13.16) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VOR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VOR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.19x
Industry
18.26x
Market
12.7x
VOR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-4.74x
Industry
4.74x
VOR's financial health
Profit margin
Revenue
$0.0
Net Income
-$219.6M
Profit Margin
0%
VOR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$506.7M
Liabilities
$657.2M
Debt to equity
-4.37
VOR's short-term assets ($500.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VOR's long-term liabilities ($641.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VOR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VOR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$38.2M
Investing
-$263.2M
Financing
$74.9M
VOR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VOR vs Biotech Stocks
Vor Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.